PACIRA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.42 USD | -1.47% |
|
+8.12% | -12.80% |
| May. 10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
| May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
Presenter SpeechDavid Stack (Executives)[Audio Gap] given the fact that we have some opportuni...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
29.42
USD
Average target price
44.9
USD
Spread / Average Target
+52.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.80% | 1.37B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Transcript : Pacira BioSciences, Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 09
